Related references
Note: Only part of the references are listed.International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A. Arber et al.
BLOOD (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury et al.
LEUKEMIA (2022)
SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis
Sandra Huber et al.
LEUKEMIA (2022)
The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes
Panagiotis T. Diamantopoulos et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients
Kamila Janusz et al.
ANNALS OF HEMATOLOGY (2021)
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes
Matteo Bersanelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?
Rami Komrokji et al.
LEUKEMIA & LYMPHOMA (2021)
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS
Luca Malcovati et al.
BLOOD (2020)
Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Elsa Bernard et al.
NATURE MEDICINE (2020)
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
Detlef Haase et al.
LEUKEMIA (2019)
Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myelodysplasies
Louis Drevon et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Clinicopathologic evaluation of cytopenic patients with isolated trisomy 8: a detailed comparison between idiopathic cytopenia of unknown significance and low-grade myelodysplastic syndrome
Kseniya Petrova-Drus et al.
LEUKEMIA & LYMPHOMA (2017)
Dynamics of clonal evolution in myelodysplastic syndromes
Hideki Makishima et al.
NATURE GENETICS (2017)
The high frequency of the U2AF1 S34Y mutation and its association with isolated trisomy 8 in myelodysplastic syndrome in Asians, but not in Caucasians
Seon Young Kim et al.
LEUKEMIA RESEARCH (2017)
Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes
Feng Xu et al.
SCIENTIFIC REPORTS (2017)
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8
Takaaki Konuma et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts
Luca Malcovati et al.
BLOOD (2015)
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
T. Haferlach et al.
LEUKEMIA (2014)
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
Luca Malcovati et al.
BLOOD (2013)
The genetic basis of myelodysplasia and its clinical relevance
Mario Cazzola et al.
BLOOD (2013)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes
Silvia Saumell et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
Julie Schanz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Martin Jaedersten et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes:: evidence from a core dataset of 2124 patients
Detlef Haase et al.
BLOOD (2007)
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes:: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
CS Cutler et al.
BLOOD (2004)
The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology
K Paulsson et al.
CANCER GENETICS AND CYTOGENETICS (2001)
Share Paper
